These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25156795)

  • 21. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells].
    Smit MC; Haverkamp MH; Weersink AJ; Boucher CA; Hoepelman IM
    Ned Tijdschr Geneeskd; 2004 Nov; 148(47):2330-4. PubMed ID: 15587052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
    Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
    AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determinants of immunological and virological responses to antiretroviral therapy amongst HIV-infected adults in central Argentina: negative influence of hepatitis C infection.
    Farías AA; Kremer LE; Allende L; Díaz Mdel P; Pisano MB; Contigiani MS; Ré VE
    Trans R Soc Trop Med Hyg; 2013 Jul; 107(7):432-7. PubMed ID: 23761392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
    Adjé-Touré CA; Cheingsong R; Garcìa-Lerma JG; Eholié S; Borget MY; Bouchez JM; Otten RA; Maurice C; Sassan-Morokro M; Ekpini RE; Nolan M; Chorba T; Heneine W; Nkengasong JN
    AIDS; 2003 Jul; 17 Suppl 3():S49-54. PubMed ID: 14565609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.
    Nemes E; Lugli E; Nasi M; Ferraresi R; Pinti M; Bugarini R; Borghi V; Prati F; Esposito R; Cossarizza A; Mussini C
    AIDS; 2006 Oct; 20(16):2021-32. PubMed ID: 17053348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in levels of T cell subpopulations to monitor the response to antiretroviral therapy among HIV-1-infected patients during two years of HIV-1 replication suppression.
    Zhang JC; Zhang HJ; Li Y; Jing D; Liu Q; Zhao K; Liu QQ; Zhuang Y; Kang WZ; Sun YT
    Scand J Infect Dis; 2013 May; 45(5):368-77. PubMed ID: 23186319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in hepatitis C viral response after initiation of highly active antiretroviral therapy and control of HIV viremia in chronically co-infected individuals.
    Kottilil S; Jagannatha S; Lu A; Liu S; McLaughlin M; Metcalf JA; Dewar R; Campbell C; Koratich C; Maldarelli F; Masur H; Polis MA
    HIV Clin Trials; 2004; 5(1):25-32. PubMed ID: 15002084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution of HVR-1 quasispecies after 1-year treatment in HIV/HCV-coinfected patients according to the pattern of response to highly active antiretroviral therapy.
    Solmone M; Girardi E; Lalle E; Abbate I; D'Arminio Monforte A; Cozzi-Lepri A; Alessandrini A; Piscopo R; Ebo F; Cosco L; Antonucci G; Ippolito G; Capobianchi MR; ;
    Antivir Ther; 2006; 11(1):87-94. PubMed ID: 16518964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD8+ T-cell numbers predict the response to antiviral therapy in HIV-1-infected children.
    Resino S; Bellón JM; Sánchez-Ramón S; Gurbindo D; León JA; Muñoz-Fernández MA
    Pediatr Res; 2003 Feb; 53(2):309-12. PubMed ID: 12538791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe.
    Soriano V; Mocroft A; Peters L; Rockstroh J; Antunes F; Kirkby N; de Wit S; Monforte Ad; Flisiak R; Lundgren J;
    J Antimicrob Chemother; 2010 Mar; 65(3):548-55. PubMed ID: 20051475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors associated with therapeutic success in HIV-positive individuals in southern Brazil.
    Silveira MP; Maurer P; Guttier MC; Moreira LB
    J Clin Pharm Ther; 2015 Apr; 40(2):192-5. PubMed ID: 25422132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection.
    Lacabaratz-Porret C; Urrutia A; Doisne JM; Goujard C; Deveau C; Dalod M; Meyer L; Rouzioux C; Delfraissy JF; Venet A; Sinet M
    J Infect Dis; 2003 Mar; 187(5):748-57. PubMed ID: 12599048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impaired CD4+ cell recovery during antiretroviral therapy in patients with HIV resistance mutations.
    Sühs KW; Stoll M; Diem R; Schmidt RE; Heiken H
    Arch Virol; 2012 Mar; 157(3):433-40. PubMed ID: 22179846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
    Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of GBV-C infection in HIV-1 infected patients.
    Canducci F; Uberti Foppa C; Boeri E; Racca S; Gallotta G; Grasso MA; Calori G; Lazzarin A; Clementi M
    J Biol Regul Homeost Agents; 2003; 17(2):191-4. PubMed ID: 14518722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.